FLT3 and leukemia: Similarly a randomized, phase 3 trial showed long-lasting improved overall survival (OS) and leukemia-free survival (LFS—5-year follow up) in patients receiving sorafenib as post-HCT maintenance (5), confirming the results highlighted in a meta-analysis (6) evaluating 12 studies and more than 2,000 patients with a clear benefit on OS and LFS from post-transplant FLT3-i maintenance.